Asset profile

Toripalimab

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-12-30.

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(31 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (7)

September 2026 (2)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-09-01 · NCT07169994 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder CancerRecruiting

Est. primary completion 2026-09-01 · NCT06852287 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)

Phase 2TNBC, Triple Negative Breast CancerRecruiting

Est. primary completion 2026-10-01 · NCT06682195 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (4)

Phase 2Breast CancerRecruiting

Est. primary completion 2026-12 · NCT06914440 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12-01 · NCT06426511 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2026-12-30 · NCT04772287 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12-31 · NCT05798845 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (12)

January 2027 (2)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-01 · NCT07493980 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-01-31 · NCT06269211 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (2)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-02-28 · NCT06623136 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)

Phase 3HR+/HER2- Breast CancerRecruiting

Est. primary completion 2027-03-23 · NCT06977893 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (3)

Phase 2Triple Negative Breast NeoplasmsNot yet recruiting

Est. primary completion 2027-06 · NCT07040644 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-06 · NCT06437977 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerRecruiting

Est. primary completion 2027-06-30 · NCT06878625 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 2Advanced Breast CancerRecruiting

Est. primary completion 2027-08 · NCT07540533 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 2TNBC - Triple-Negative Breast CancerNot yet recruiting

Est. primary completion 2027-11-30 · NCT07101614 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-18 · NCT07286942 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2ER+/HER2- Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT06964906 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (10)

January 2028 (3)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-01-01 · NCT07358689 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC, Triple Negative Breast CancerRecruiting

Est. primary completion 2028-01-04 · NCT07457359 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC - Triple-Negative Breast Cancer, PD-L1 PositiveNot yet recruiting

Est. primary completion 2028-01-30 · NCT07244874 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (2)

Phase 2HR Positive/HER2 Low Breast CancerRecruiting

Est. primary completion 2028-02-01 · NCT07383818 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast CancerNot yet recruiting

Est. primary completion 2028-02-21 · NCT07410234 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 2/3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-08-05 · NCT06984588 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-10-31 · NCT07251582 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-11-30 · NCT06706219 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-12-30 · NCT07039656 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC - Triple-Negative Breast CancerNot yet recruiting

Est. primary completion 2028-12-31 · NCT07256964 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)

June 2029 (1)

Phase 2Breast CancerRecruiting

Est. primary completion 2029-06-30 · NCT07378306 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2029 (1)

Phase 2Triple Negative Breast Cancer (TNBC)Recruiting

Est. primary completion 2029-09 · NCT06636981 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.